噻唑烷二酮类药物致不良反应文献分析

• 药品评价-安全性研究 • 上一篇下一篇

噻唑烷二酮类药物致不良反应文献分析

张士勇

安徽省蚌埠市第三人民医院药学部

收稿日期:2014-04-01 修回日期:2014-06-03 出版日期:2014-08-25 发布日期:2014-08-25

Adverse drug reactions induced by Thiazolidinediones

The Third People’s Hospital Bengbu

Received:2014-04-01 Revised:2014-06-03 Online:2014-08-25 Published:2014-08-25

摘要/Abstract

摘要： 目的：分析噻唑烷二酮类药物不良反应的发生情况及临床特点,为合理用药提供参考。方法：检索噻唑烷二酮类在中国上市以来CNKI、VIP数据库收载的不良反应文献进行统计分析。结果：噻唑烷二酮类不良反应的文献报道共24例次；年龄60岁以上发生率较高(16例,66.7％)；多发生在用药1月后(11例,45.8%)；分别涉及红细胞异常、心血管系统一般损害、代谢和营养障碍、肝胆系统损害等多个系统/器官。结论：临床合理使用噻唑烷二酮类药物的同时,加强用药监测,以减少不良反应的发生。

Abstract: OBJECTIVE：To analyze the general patterns and characteristics of adverse drug reactions (ADR ) induced by thiazolidinediones (TZDs) and provide reference for clinical medicination. METHODS：ADR of TZDs reported in Chinese medical science journals were retrieved from CNKI literature base and VIP database were collected and analyzed statistically．RESULTS：A total of 24 ADRs were identified and included in the analysis. Patients over the age of 60 years showed the highest ineidence(n=11,45.8％)．ADR of TZDs always attack after 1 month(n=11,45.8％)．T heir ADRs were involved in many system s such as red blood cell disorders, cardiovascular general disorders,metabolic and nutritional disorders,liver and biliary system disorders.CONCLUSION：Clinicians should use TZDs reasonably and tighten monitoring on its using to reduce the incidences of ADR.

张士勇. 噻唑烷二酮类药物致不良反应文献分析[J]. .

参考文献

[1] Seto-Young D, Avtanski D, Parikh G. , et al. Rosiglitazone and pioglitazone inhibit estrogen synthesis in human granulosa cells by interfering with androgen binding to aromatase. [ J ] . Horm Metab Res. 2011,43(4):250-256.
[2] Kahn SE, Haffner SM, Heise MA, et al. Glycemicdurability of rosig litazone, metformin, orglyburide monotherapy [J].N Engl J Med, 2006, 355 ( 23 ):2427-2443.
[3] Shvidel L, Arcavi L, Sigler E．Symptomatic anemia induced by rosiglitazone.e[J]．Eur J Intern Med. 2007,18(4):348.
[4] Clevidence DE, Juckett MB, Lucarelli MJ. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. [J]. WMJ. 2009,
[5] Berriai R,Glass L,Mahankali A,et a1．Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus [J]．Clinical Clin Pharmacol Ther.,2007,82(3)：275-281．
[7] Yki-Jarvinen H, Thiazolidinediones. [J]. N Engl J Med2004,351: 1106-1118.
[8] Mudal iar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabet es: incidence, pathophysiology, and clinical implications[ J] . Endocr Pract , 2003, 9(5) ( 406- 416.
[9] Nissen SE,Wolski K．Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J]．New Eng J Med,2007,356(24)：2457-2471．
[10] http://www.cdr.gov.cn/jjkx_258/ywjjkx/2014/201402/t20140224_7497.html
[11] Tan M, Johns D, Gonzalez GG, et al . Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mell itus: A mult icenter, randomized,double-bl ind, paralle-group trial[ J] . Clin Ther, 2004, 26( 5) (680- 693.
[12] Canadian Adverse Drug Reaction Monitoring Program.Rosiglitazone: hepatic, cardiac and hematolodical reactions[ J] .Canadian Advers Drug Reaction Newsletter , 2001, 11: 2.
[13] Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus - current clinical evidence [ J] . Drugs. 2003;63(13):1373-1405.
[14] 王丽,邵闳. 盐酸吡格列酮致心包积液1例[J].疑难病杂志,2007,6(5)：301
[15] 王波纹. 吡格列酮致胃出血1例[J]. ]．新医学,2010,31(9)：75．
[16] 沈浩,胡玲. 盐酸吡格列酮致上消化道出血1例报告[J]. 南昌大学学报(医学版),2011,51(11)：106
[17] 谢福军,陈艳秋. 罗格列酮相关的剥脱性角质松解症[J]. 药物不良反应杂志,2009,11(1)：50-51.
[18] 赵惊奇,贺罡. 马来酸罗格列酮片致剥脱性皮炎1 例[J]. 中国药物警戒,2013,10(2)：123.
[19] 韩静. 口服马来酸罗格列酮片致腮腺肿胀2例[J]. 中国医院药学杂志,2012,32(22)：1857-1858
[20] 胡文凤. 罗格列酮诱发频发室性早搏1例[J]. 中国新药与临床杂志,2008,27(7)：559
[21] 匡培清,周平南,洪淇. 罗格列酮致双侧颞颌关节痛1例[J]. 内科,2010,5 (4)：427
[22] Canadian Adverse Reaction Newsletter,January 2006,16(1)．(hhp：//www.he-sc.Gc.ca)